REG - AstraZeneca PLC - Divestment of hypertension medicines completed

AstraZenecaAnnouncement

02/03/2020 07:00

RNS Number : 6419E
  
AstraZeneca PLC
  
02 March 2020
  
 

2 March 2020 07:00 GMT
 
AstraZeneca completes divestment agreement with

Atnahs Pharma for established hypertension medicines
 
AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).
 
Financial considerations
Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to $40m between 2020 and 2022. The upfront payment will be reported in AstraZeneca's financial statements within Other Operating Income & Expense in the first quarter of 2020.
 
Inderal
Inderal (propranolol) is a beta-blocker and is predominantly used to treat tremors, angina, hypertension, arrhythmias, and other heart or circulatory conditions. It is also used to reduce the severity and frequency of migraine.
 
Tenormin and Tenoretic
Tenormin (atenolol) is a beta-blocker that is used to treat angina and hypertension, as well as certain kinds of arrhythmias. It is also used to lower the risk of death after a heart attack. Tenoretic is a fixed-dose combination of atenolol (beta-blocker) and chlorthalidone (diuretic), used to treat high blood pressure.
 
Zestril and Zestoretic
Zestril (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. Zestril may also be used to improve survival after a heart attack. Zestoretic is a fixed-dose combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (diuretic) used to treat hypertension.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 



Media Relations












Gonzalo Viña 






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Angela Fiorin


BioPharmaceuticals


+44 1223 344 690




Jennifer Hursit


Other 


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals 
(Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)
 


+44 203 749 5631




Tom Waldron


Other medicines


+44 7385 033 717




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
Adrian Kemp

Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCUUANRRRUORRR